Citation

BibTex format

@article{Whitlock:2024:10.1080/25787489.2024.2400453,
author = {Whitlock, G and Fidler, S and Clarke, A and Kang, S and Xhikola, A and Milinkovic, A and Soler-Carracedo, A and Henderson, M and Adams, T and Jahan, I and Khawaja, A and Taylor, G and Boffito, M},
doi = {10.1080/25787489.2024.2400453},
journal = {HIV Research & Clinical Practice},
title = {A randomised control trial of BIC/F/TAF vs DRV/c/F/TAF in context of HIV test-and-treat, BicTnT},
url = {http://dx.doi.org/10.1080/25787489.2024.2400453},
volume = {25},
year = {2024}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background:Head-to-head data for bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF; B) and darunavir/cobicistat/emtricitabine/tenofovir alafenamide (DRV/c/F/TAF; D) are lacking in the context of rapid antiretroviral therapy (ART) initiation. This study, BIC-T&T, evaluates the efficacy and tolerability of B vs D in a UK testandtreat setting.Setting:BIC-T&T was a randomised, open-label, multi-centre, study in which participants initiated ART within 14 days after confirmed HIV1 diagnosis before baseline laboratory.Methods:The primary endpoint is the virological response (HIV RNA < 50copies/mL) at week 12 by time-weighted average change in log10 HIV RNA recorded in viral load assays from treatment initiation to week 12, using two-sample Wilcoxon rank-sum test.Results:36 participants were randomised: 94% were male, 53% white; mean (SD) age was 35 years (11.8). Baseline mean (±SD) log10 HIV-RNA was 4.79 (± 0.87) log10 copies/mL and CD4 505 (±253) cells/mm3. The mean (±SD) time from confirmed HIV diagnosis to ART initiation was 7.9 (± 3.7) days. The time-weighted mean decrease in log10 HIV RNA from treatment initiation to week 12 was significantly greater in B in comparison to D (3.1 vs. 2.6 log10 copies/mL, p < 0.001). Both regimens demonstrated good tolerability with infrequent laboratory abnormalities and no grade 3 or 4 adverse events.Conclusion:In this first head-to-head study in the context of ART initiation, HIV RNA decline from baseline to week 12 was significantly more rapid for BIC/F/TAF compared with DRV/c/F/TAF.
AU  - Whitlock,G
AU  - Fidler,S
AU  - Clarke,A
AU  - Kang,S
AU  - Xhikola,A
AU  - Milinkovic,A
AU  - Soler-Carracedo,A
AU  - Henderson,M
AU  - Adams,T
AU  - Jahan,I
AU  - Khawaja,A
AU  - Taylor,G
AU  - Boffito,M
DO  - 10.1080/25787489.2024.2400453
PY  - 2024///
SN  - 2578-7489
TI  - A randomised control trial of BIC/F/TAF vs DRV/c/F/TAF in context of HIV test-and-treat, BicTnT
T2  - HIV Research & Clinical Practice
UR  - http://dx.doi.org/10.1080/25787489.2024.2400453
UR  - http://hdl.handle.net/10044/1/114382
VL  - 25
ER  -
Download